PHARMACOKINETICS (PK) OF CRIZOTINIB (PF-02341066), A DUAL ALK/C-MET INHIBITOR, FOLLOWING ADMINISTRATION OF MULTIPLE ORAL DOSES TO PATIENTS WITH ADVANCED ALK-POSITIVE NSCLC IN CHINA

被引：0
|
作者：
Tan, Weiwei [1 ]
O'Gorman, Melissa [2 ]
Lanzalone, S. [3 ]
Wilner, Keith [1 ]
Boyd, Jason [1 ]
Liu, Xiaoquing [4 ]
Wu, Yi-long [5 ,6 ]
Qin, Shukui [7 ]
Han, Baohui [8 ]
Shi, Yuankai [9 ,10 ]
机构：
[1] Pfizer Oncol, La Jolla, CA USA
[2] Pfizer Oncol, Groton, CT USA
[3] Pfizer Oncol, Pfizer Italia Srl, Milan, Italy
[4] 307 Hosp Pla, Dept Lung Canc, Beijing, Peoples R China
[5] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[6] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[7] Nanjing Bayi Hosp, Nanjing, Jiangsu, Peoples R China
[8] Shanghai Chest Hosp, Dept Pulm Med, Shanghai, Peoples R China
[9] Chinese Acad Med Sci, Canc Inst Hosp Cih, Beijing, Peoples R China
[10] Peking Union Med Coll, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 11期
关键词：
crizotinib; pharmacokinetics; ALK; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-039
引用
收藏
页码：S491 / S491
页数：1
相关论文
共 15 条
  • [1] Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.
    Tan, W.
    Wilner, K. D.
    Bang, Y.
    Kwak, E. L.
    Maki, R. G.
    Camidge, D. R.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Clark, J. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC)
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Camidge, D. R.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Clark, J. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [3] CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066), IN ALK-POSITIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Camidge, D. R.
    Bang, Y.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Solomon, B.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 123 - 123
  • [4] Antitumor efficacy of crizotinib (PF-02341066), a potent and selective ALK and c-Met RTK inhibitor, in EML4-ALK driven NSCLC tumors in vitro and in vivo
    Zou, Helen Y.
    Li, Qiuhua
    Lee, Joseph
    Engstrom, Lars
    Lu, Melissa West
    Young, Alex
    Timofeevski, Sergei
    Dinh, Dac M.
    Yamazaki, Shinji
    Lam, Justine
    Feng, Zheng
    Nickel, Jeffrey
    Lappin, Patrick B.
    Nichols, Tim
    Wong, Anthony
    Snider, Brittany
    Gukasyan, Hovhannes
    Bender, Steve
    Zabludoff, Sonya
    Smeal, Tod
    Christensen, James R.
    [J]. CANCER RESEARCH, 2011, 71
  • [5] Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066
    Kwak, E. L.
    Camidge, D. R.
    Clark, J.
    Shapiro, G. I.
    Maki, R. G.
    Ratain, M. J.
    Solomon, B.
    Bang, Y.
    Ou, S.
    Salgia, R.
    [J]. EJC SUPPLEMENTS, 2009, 7 (03): : 8 - 8
  • [6] Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066
    Kwak, E. L.
    Camidge, D. R.
    Clark, J.
    Shapiro, G. I.
    Maki, R. G.
    Ratain, M. J.
    Solomon, B.
    Bang, Y.
    Ou, S.
    Salgia, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] PHASE 2 DATA FOR CRIZOTINIB (PF-02341066) IN ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PROFILE 1005
    Riely, Gregory J.
    Kim, Dong-Wan
    Crino, Lucio
    Janne, Pasi A.
    Blackhall, Fiona H.
    Camidge, David R.
    Hirsh, Vera
    Mok, Tony S. K.
    Solomon, Ben
    Soria, Jean-Charles
    Park, Keunchil
    Gadgeel, Shirish M.
    Martins, Renato G.
    Han, Ji-Youn
    De Pas, Tommaso
    Bottomley, Andrew
    Polli, Anna
    Petersen, Jennifer A.
    Tassell, Vanessa R.
    Shaw, Alice T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S411 - S412
  • [8] Clinical activity of the oral ALK and MET inhibitor PF-02341066 in non-small lung cancer (NSCLC) with EML4-ALK translocations
    Shaw, Alice T.
    Costa, Daniel B.
    Iafrate, A. J.
    Dezube, Bruce J.
    Shapiro, Geoffrey, I
    Bang, Yung J.
    Janne, Pasi A.
    Lynch, Thomas J.
    Maki, Robert G.
    Camidge, D. R.
    Solomon, Benjamin
    Kwak, Eunice L.
    Tan, Weiwei
    Chen, Isan
    Christensen, Jamie
    Wilner, Keith
    Clark, Jeffrey W.
    Salgia, Ravi
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S305 - S306
  • [9] Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)
    Solomon, B.
    Bang, Y. J.
    Camidge, D. R.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    [J]. EJC SUPPLEMENTS, 2010, 8 (07): : 117 - 117
  • [10] Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
    Cui, J. Jean
    Tran-Dube, Michelle
    Shen, Hong
    Nambu, Mitchell
    Kung, Pei-Pei
    Pairish, Mason
    Jia, Lei
    Meng, Jerry
    Funk, Lee
    Botrous, Iriny
    McTigue, Michele
    Grodsky, Neil
    Ryan, Kevin
    Padrique, Ellen
    Alton, Gordon
    Timofeevski, Sergei
    Yamazaki, Shinji
    Li, Quhua
    Zou, Helen
    Christensen, James
    Mroczkowski, Barbara
    Bender, Steve
    Kania, Robert S.
    Edwards, Martin P.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (18) : 6342 - 6363
12